To further examine the ability of the BiCisCAR to overcome the heterogenous expression of GPC2 and CD276 on NB, we next used CRISPR/Cas9 to create GPC2- or CD276-null mutations in 2 NB cell lines (IMR5 and IMR32). This evidence concerns the gene CD276 and neuroblastoma.